Conatus Pharmaceuticals Inc. (CNAT) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Current Quarter Estimates for CNAT
In the past 30 days, 1 estimate has gone higher for Conatus Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 43 cents a share 30 days ago, to a loss of 35 cents today, a move of 18.6%.
Current Year Estimates for CNAT
Meanwhile, Conatus Pharmaceuticals’ current year figures are also looking quite promising, with 3 estimates moving higher in the past month, compared to only 1 lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.56 per share 30 days ago to $1.25 per share today, a move of 19.9%.
The stock has also started to move higher lately, adding 19.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>